Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumabas - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antinavikiniai vaistai - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatos navikai, kastracija-atsparus - terapiniai radiofarmaciniai preparatai - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

eli lilly nederland b.v. - ramucirumab - skrandžio navikai - antinavikiniai vaistai - skrandžio cancercyramza kartu su paklitakseliu gydomi suaugę pacientai, sergantys progresavusia skrandžio vėžio, ar gastro-oesophageal sankryžos adenokarcinoma su ligos progresavimo po prieš platinos ir fluoropyrimidine chemoterapija. cyramza monotherapy fluorouracilu ir folino suaugusių pacientų su papildoma skrandžio vėžio, ar gastro-oesophageal sankryžos adenokarcinoma su ligos progresavimo po prieš platinos arba fluoropyrimidine chemoterapija, kuriems gydymas kartu su paklitakseliu nėra tinkamas. storosios žarnos cancercyramza, kartu su folfiri (irinotecan, folinic rūgšties ir 5‑fluorouracilu), yra nurodyta gydyti suaugusiems pacientams, sergantiems metastazavusiu gaubtinės ir tiesiosios žarnos vėžio (mcrc) su ligos progresavimo arba po prieš terapija su bevacizumab, oksaliplatinos ir fluoropyrimidine. nesmulkialąstelinio plaučių cancercyramza kartu su docetaxel fluorouracilu ir folino suaugusių pacientų su lokaliai išplitusio arba metastazavusio nesmulkialąstelinio plaučių vėžio ligos progresavimo po platinos pagrindu chemoterapija. hepatocellular carcinomacyramza monotherapy fluorouracilu ir folino suaugusių pacientų su pažangiomis ar unresectable hepatocellular karcinoma, kurie turi serumo alfa fetoprotein (afp nuotr.) ≥ 400 ng/ml ir kurie anksčiau buvo elgiamasi su sorafenib.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., ul. fabryczna 5, pl-00446 warszawa (lenkija). - glikolio rūgštis - veikliosios medžiagos cas nr.: 79-14-1, eb nr.: 201-180-5, veikliosios medžiagos pavadinimas: glikolio rūgštis, koncentracija: 3.5% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, pl-02305 warszawa (lenkija). - natrio hipochloritas, kuriame yra ... aktyvaus chloro - veikliosios medžiagos cas nr.: 7681-52-9, eb nr.: 231-668-3, veikliosios medžiagos pavadinimas: natrio hipochloritas, kuriame yra ... aktyvaus chloro, koncentracija: 4% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, pl-02305 warszawa (lenkija). - natrio hipochloritas, kuriame yra ... aktyvaus chloro - veikliosios medžiagos cas nr.: 7681-52-9, eb nr.: 231-668-3, veikliosios medžiagos pavadinimas: natrio hipochloritas, kuriame yra ... aktyvaus chloro, koncentracija: 4.925% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, pl-02305 warszawa (lenkija). - glikolio rūgštis; glikolio rūgštis - veikliosios medžiagos cas nr.: 79-14-1, eb nr.: 201-180-5, veikliosios medžiagos pavadinimas: glikolio rūgštis, koncentracija: 4.557% , veiklioji; veikliosios medžiagos cas nr.: 79-14-1, eb nr.: 201-180-5, veikliosios medžiagos pavadinimas: glikolio rūgštis, koncentracija: 4.557% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, pl-02305 warszawa (lenkija) - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, pl-02305 warszawa (lenkija). - natrio hipochloritas, kuriame yra ... aktyvaus chloro - veikliosios medžiagos cas nr.: 7681-52-9, eb nr.: 231-668-3, veikliosios medžiagos pavadinimas: natrio hipochloritas, kuriame yra ... aktyvaus chloro, koncentracija: 10% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

diversey polska sp. z o.o., al. jerozolimskie 134, 02-305 warszawa (lenkija). - glikolio rūgštis - veikliosios medžiagos cas nr.: 79-14-1, eb nr.: 201-180-5, veikliosios medžiagos pavadinimas: glikolio rūgštis, koncentracija: 3.5% , veiklioji - maisto ir pašarų sritis